AGLE Aeglea BioTherapeutics, Inc.
Latest News

$10.31-0.99 (-8.76%)3:47 PM 10/04/23

NASDAQ | $USD | Realtime

News

Show Full Stories

This feature available only for pro users

Type:

Date Range:

Aeglea BioTherapeutics announces 1-for-25 reverse stock split

Aeglea BioTherapeutics appoints Burrows as CFO, King-Jones as CLO

Aeglea BioTherapeutics GAAP EPS of -$2.27

Aeglea initiated with Buy at Stifel citing potential in IBD space

Aeglea BioTherapeutics acquires Spyre; microcap up 360%

Aeglea BioTherapeutics GAAP EPS of -$0.20 misses by $0.03, revenue of $0.2M beats by $0.12M

Aeglea slumps ~25% as trial results trigger strategic options, workforce reduction

Aeglea BioTherapeutics GAAP EPS of -$0.99 beats by $0.03, revenue of $2.33M beats by $0.1M

Aeglea BioTherapeutics names Jeffrey Goldberg as CEO; shares slide on corporate and clinical development strategy

Aeglea BioTherapeutics appoints Linda Neuman as chief medical officer

Aeglea Bio regains Nasdaq compliance

Aeglea BioTherapeutics upgraded to overweight at Wells Fargo on pegtarviliase optimism

Aeglea stock dips as FDA places partial hold on enrolling under 18 patients in metabolic disorder trial

Aeglea Bio announces departure of CEO, corporate restructuring

Aeglea stock jumps ~58% on EMA validation of marketing application for enzyme pegzilarginase

Aeglea BioTherapeutics GAAP EPS of -$0.27 beats by $0.04, revenue of $0.63M misses by $0.08M

Aeglea BioTherapeutics receives FDA Refuse to File letter for pegzilarginase

CRISPR, Xencor stock falls as Piper Sandler slashes price target in biotech space

Aeglea BioTherapeutics to raise $45M in stock and warrants offering

Aeglea BioTherapeutics GAAP EPS of -$0.37, revenue of $1.36B

Aeglea stock soars 24% on filing seeking FDA approval of pegzilarginase for rare disorder

Aeglea surges 40% following additional phase 3 data for pegzilarginase for rare disorder

Aeglea BioTherapeutics GAAP EPS of -$1.00 beats by $0.02, revenue of $18.73M beats by $1.33M

Aeglea director resigns after disagreement on financing plans

Aeglea BioTherapeutics slumps 5% on withdrawn offering

Aeglea BioTherapeutics announces proposed public offering

Aeglea says pivotal trial for pegzilarginase in Arginase 1 Deficiency met main goal

Aeglea BioTherapeutics EPS misses by $0.01

Aeglea BioTherapeutics reports Q2 results

Aeglea posts 20 week data from early-stage pegzilarginase Arginase 1 Deficiency study

Aeglea Biotherapeutics names Jonathan Alspaugh as chief financial officer

Aeglea Biotherapeutics doses first patient in early-stage AGLE-177 Homocystinuria study

Aeglea BioTherapeutics EPS misses by $0.14

Aeglea completes patient randomization in late-stage pegzilarginase trial

Aeglea inks deal with Immedica for Europe, Middle East rights to rare disease therapy

Aeglea BioTherapeutics EPS beats by $0.04

Aeglea Biotherapeutics climbs 5.5% on ownership disclosure

Aeglea Biotherapeutics CFO Charles York to step down

Aeglea again pushes back arginase 1 deficiency trial enrollment to March

Aeglea Bio's ACN00177 nabs Rare Pediatric status for inherited metabolic disorder

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.

Is this happening to you frequently? Please report it on our feedback forum.

If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.